SCHEMBL2884823

SCHEMBL2884823

CC(C)c1cc(C2(c3cc(C(C)C)c(O)c(C(C)C)c3)c3ccccc3-c3ccccc32)cc(C(C)C)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.50
ESR2 Q92731 1/20 0.50
EGFR P00533 1/20 0.46
ERBB2 P04626 1/20 0.46
IGF1R P08069 1/20 0.46
PDGFRB P09619 1/20 0.46
NOX4 Q9NPH5 1/20 0.46
GABRA1 P14867 6/20 0.44
GABRB1 P18505 5/20 0.44
LMNA P02545 4/20 0.44
GABRB2 P47870 3/20 0.44
CYP1A2 P05177 3/20 0.44
CYP3A4 P08684 3/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
HIF1A Q16665 2/20 0.44
FAAH O00519 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
GABRG2 P18507 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL382542 0.83 ESR1 (0.64) ESR1ESR2EGFRERBB2IGF1R
SCHEMBL29445696 0.83 ESR1 (0.64) ESR1ESR2EGFRERBB2IGF1R
SCHEMBL18101032 0.83 ESR1 (0.43) ESR1ESR2EGFRERBB2IGF1R
SCHEMBL29580634 0.83 LMNA (0.50) ESR1ESR2EGFRERBB2IGF1R
SCHEMBL2050108 0.83 LMNA (0.50) ESR1ESR2EGFRERBB2IGF1R
SCHEMBL18100870 0.81 ESR1 (0.41) ESR1ESR2EGFRERBB2IGF1R
SCHEMBL9324920 0.78 ESR1 (0.49) ESR1ESR2LMNACYP1A2CYP3A4
SCHEMBL30806212 0.77 ESR1 (0.69) ESR1ESR2LMNACA1CA2
SCHEMBL515744 0.77 ESR1 (0.69) ESR1ESR2LMNACA1CA2
SCHEMBL29378579 0.77 ESR1 (0.69) ESR1ESR2LMNACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012042058-A1 IMPACT RESISTANCE MODIFIERS FOR EPOXY RESIN COMPOSITIONS SIKA TECHNOLOGY AG (CH) 2012-04-05 WO disclosed
US-7781540-B2 Resin composition and molded articles thereof OSAKA GAS CO., LTD. (JP) 2010-08-24 US disclosed
US-7772356-B2 Infrared absorption filter OSAKA GAS CO., LTD. (JP) 2010-08-10 US disclosed
US-7645534-B2 Membrane electrode assembly for solid polymer electrolyte fuel cell HONDA MOTOR CO., LTD. (JP) 2010-01-12 US disclosed
US-20090149625-A1 AROMATIC COMPOUND HAVING FLUORENE SKELETON AND POLYARYLENE HAVING SULFONIC ACID GROUP JSR CORPORATION (JP) 2009-06-11 US disclosed
EP-1808461-B1 RESIN COMPOSITION AND MOLDED OBJECT THEREOF TEIJIN CHEMICALS LTD (JP) 2009-03-11 EP disclosed
EP-2011812-A1 AROMATIC COMPOUND HAVING FLUORENE SKELETON AND POLYARYLENE HAVING SULFONIC ACID GROUP JSR Corporation (JP) 2009-01-07 EP disclosed
US-20080085955-A1 Resin Composition And Molded Articles Thereof OSAKA GAS CO., LTD. (JP) 2008-04-10 US disclosed
US-20070293606-A1 Infrared Absorption Filter OSAKA GAS CO., LTD. (JP) 2007-12-20 US disclosed
US-20070248865-A1 Membrane electrode assembly for solid polymer electrolyte fuel cell HONDA MOTOR CO., LTD. 2007-10-25 US disclosed
EP-1808461-A1 RESIN COMPOSITION AND MOLDED OBJECT THEREOF Teijin Chemicals, Ltd. (JP) 2007-07-18 EP disclosed
EP-1804093-A1 INFRARED ABSORBING FILTER OSAKA GAS CO., LTD. (JP) 2007-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149625-A1 AROMATIC COMPOUND HAVING FLUORENE SKELETON AND POLYARYLENE HAVING SULFONIC ACID GROUP AFF2, FGFR1, FUS ESR1 843/4885ESR2 992/4885EGFR 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.